Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Arimistane and Enclomiphene — mechanism, side effects, legal status, and pricing.
Arimistane is a non-peptide C19 steroidal compound (androstane-based) marketed as a mechanism-based aromatase inhibitor and sold as a gray-market bodybuilding supplement ingredient. It is a 7-keto-DHEA metabolite/degradation product with no approved therapeutic use. The FDA determined in 2021 that arimistane does not meet the definition of a dietary ingredient and fails GRAS criteria for food use. It is prohibited under the WADA Prohibited List (Section S4, Aromatase Inhibitors) and was added to the list in 2017.
Enclomiphene is the trans-stereoisomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production. It is not a peptide, but is widely tracked in the peptide and TRT community as an off-label, compounded alternative to testosterone replacement therapy for men who wish to preserve fertility. Clomiphene itself is a ~60:40 mixture of enclomiphene (trans, estrogen-antagonist) and zuclomiphene (cis, weak long-acting estrogen-agonist); isolating the trans-isomer is intended to deliver the HPG-axis effect without the zuclomiphene-driven side effects.
Arimistane
Enclomiphene
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Arimistane
No pricing data yet.
Check Arimistane prices →Enclomiphene
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check Enclomiphene prices →COA corpus from Disclosed Labs — independently tested batches only.
Arimistane
No COA data yet.
Submit testing data →Enclomiphene
3
COAs
99.6%
Avg purity
1
Labs
No registered efficacy or safety clinical trials exist for arimistane. The only human data are two small anti-doping analytical studies: (1) a single 25 mg oral dose in 3 healthy volunteers produced up to 15 novel urinary metabolites, with parent compound detected in the sulfate fraction and no relevant acute effects on the steroid profile; (2) a separate single-dose study (3 volunteers, up to 10 hours) identified 12 additional reduced/hydroxylated urinary metabolites and detected unchanged parent in urine. In vitro (human placental microsomes): the close analog androst-5-ene-7,17-dione is a time-dependent, NADPH-dependent suicide substrate of aromatase; a series of related androsta-3,5-dien-7-ones/androst-5-en-7-ones competitively inhibited aromatase (Ki 0.058–45 µM), with 17-oxo derivatives more potent than 17-beta-hydroxy derivatives. Arimistane itself was not unambiguously confirmed among the specific tested compounds in the latter study.
Key references
Wiehle et al. (BJU Int 2013, PMID 23875626) established pharmacokinetics and demonstrated testosterone restoration to the normal range in men with secondary hypogonadism. Kaminetsky et al. (J Sex Med 2013, PMID 23530575) showed enclomiphene raised testosterone and sperm counts while testosterone gel suppressed gonadotropins and spermatogenesis. Phase 3 trials ZA-304 and ZA-305 (Kim et al., BJU Int 2016, PMID 26496621) confirmed efficacy in overweight/obese hypogonadal men with superior preservation of LH, FSH, and sperm counts versus AndroGel 1.62%. Despite these positive data, the FDA issued Complete Response Letters to Repros Therapeutics in 2014 and 2016; Androxal was never approved and Repros subsequently wound down. As of April 2026 no FDA-approved enclomiphene exists. It is dispensed off-label via 503A compounding pharmacies for secondary hypogonadism and post-TRT/HPTA restart.
Arimistane and Enclomiphene are both in the Hormone category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs